EBS (Emergent BioSolutions Inc.) stock: $6.80, $348.7M market cap, $139.7M cash, $790.8M EV, $426.9M fully diluted market cap. Next expected readout: Jul-27. Lead program: Blood sample collection (Botulism), Phase 4. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $139.7M |
|---|
| Debt | $581.8M |
|---|
| Net cash | -$442.1M |
|---|
| Enterprise value | $790.8M |
|---|
| Basic shares | 51.3M shares |
|---|
| Fully diluted shares | 62.8M shares |
|---|
| Fully diluted market cap | $426.9M |
|---|
| Cash per share | $2.72 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading EBS daily closes…
Loading price history…
Upcoming catalysts
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
EBS-LASV
Phase 1 · Terminated Modality: recombinant VSV-vectored vaccine
Target Lassa virus surface glycoprotein precursor
Partnerships CEPI: development funding (discontinued)
Status note Phase 1 completed with no safety concerns but missed the specified immunogenicity endpoint; CEPI funding discontinued; program closed in 2025 and will not progress to Phase 2.
EBS-MARV
Preclinical · Active Modality: recombinant VSV-vectored vaccine
Target Marburg virus surface glycoprotein precursor
Partnerships Auro Vaccines: development partner; NIAID funding Auro through Phase 1 (contract options)
Indications- Marburg virus disease (Preclinical)
Status note IND-enabling stage; Phase 1 GMP drug substance manufactured in 2025; funding discussions ongoing for GMP drug product. Company deprioritized this candidate at end of 2025 (soft; stays ACTIVE per brief).
EBS-SUDV
Preclinical · Active Modality: recombinant VSV-vectored vaccine
Target Sudan virus surface glycoprotein precursor
Partnerships Auro Vaccines: development partner; NIAID funding through Phase 1 (funding challenges in 2025)
Indications- Sudan virus disease (Preclinical)
Status note IND-enabling stage; Phase 1 GMP material not manufactured as expected in 2025 due to NIAID funding challenges. Company deprioritized this candidate at end of 2025 (soft; stays ACTIVE per brief).
NARCAN
Approved · Active Modality: intranasal spray
Indications- opioid overdose (emergency treatment) (Approved)
Status note Naloxone HCl 4mg nasal spray; FDA-approved OTC for emergency treatment of known or suspected opioid overdose.
KLOXXADO
Approved · Active Modality: intranasal spray
Partnerships Hikma Pharmaceuticals: exclusive US/Canada commercial rights to EBS obtained January 2025
Indications- opioid overdose (emergency treatment) (Approved)
Status note Naloxone HCl 8mg nasal spray (Hikma product); prescription medicine marketed by EBS in US and Canada.
ACAM2000
Approved · Active Modality: live vaccine
Partnerships US Department of War: IDIQ procurement contract (smallpox/mpox medical countermeasure)
Indications- smallpox and mpox (active immunization, high-risk) (Approved)
Status note Only single-dose smallpox vaccine licensed by FDA for active immunization against smallpox and mpox disease in high-risk persons.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.